Over the past six decades, since licensure of primaquine for anti-relapse therapy of malaria caused by Plasmodium vivax, safe access to primaquine has been denied by the absence of capacity to diagnose glucose-6-phosphate dehydrogenase (G6PD) deficiency in the impoverished rural tropics. This evidence concerns the gene G6PD and malaria.